Literature DB >> 2784066

The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation.

L Pegoraro1, F Malavasi, G Bellone, M Massaia, M Boccadoro, G Saglio, A Guerrasio, G Benetton, L Lombardi, R Coda.   

Abstract

The characteristics of a human cell line (LP-1) derived from the peripheral blood of a patient with IgG-lambda myeloma in leukemic transformation are described. The cells resemble immature plasma cells in that they exhibit a membrane phenotype that is intermediate between late B lymphocytes and plasma cells, even though they secrete IgG-lambda chains. Treatment of LP-1 cells with 12-0 tetradecanoylphorbol-13-acetate (TPA) or pokeweek mitogen (PWM) induces the appearance of surface markers and ultrastructural features typical of mature plasma cells but does not affect their proliferative activity. Molecular analysis of the cell line showed an increased expression of the c-myc protooncogene and the presence of abnormally sized transcripts. Conventional cytogenetics and pulsed-field gel electrophoresis showed no structural rearrangements of the c-myc gene, suggesting that the abnormal c-myc expression may be due to point mutations or small deletions within the gene. The LP-1 cell line is a useful model in which to study the process of B-cell maturation; such study may lead to the uncovering of unusual mechanisms of c-myc activation. Furthermore, the LP-1 cell is a potential partner in the generation of human hybridomas.

Entities:  

Mesh:

Year:  1989        PMID: 2784066

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies.

Authors:  M Massaia; A Bianchi; U Dianzani; A Camponi; C Attisano; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

2.  Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

Authors:  Y Shou; M L Martelli; A Gabrea; Y Qi; L A Brents; A Roschke; G Dewald; I R Kirsch; P L Bergsagel; W M Kuehl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

3.  Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma.

Authors:  Alberto L Horenstein; Valeria Quarona; Denise Toscani; Federica Costa; Antonella Chillemi; Vito Pistoia; Nicola Giuliani; Fabio Malavasi
Journal:  Mol Med       Date:  2016-10-13       Impact factor: 6.354

Review 4.  Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule.

Authors:  Antonella Chillemi; Gianluca Zaccarello; Valeria Quarona; Manuela Ferracin; Chiara Ghimenti; Massimo Massaia; Alberto L Horenstein; Fabio Malavasi
Journal:  Mol Med       Date:  2013-05-20       Impact factor: 6.354

5.  The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signalling.

Authors:  Antoine David; Simone Zocchi; Alexis Talbot; Caroline Choisy; Ashley Ohnona; Julien Lion; Wendy Cuccuini; Jean Soulier; Bertrand Arnulf; Jean-Christophe Bories; Michele Goodhardt; David Garrick
Journal:  Leukemia       Date:  2020-09-03       Impact factor: 11.528

6.  A Systematic Characterization of Aquaporin-9 Expression in Human Normal and Pathological Tissues.

Authors:  Cecilia Lindskog; Anna Asplund; Anca Catrina; Søren Nielsen; Michael Rützler
Journal:  J Histochem Cytochem       Date:  2016-03-29       Impact factor: 2.479

7.  Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.

Authors:  Charlotte Fristedt Duvefelt; Susanne Lub; Prasoon Agarwal; Linda Arngården; Anna Hammarberg; Ken Maes; Els Van Valckenborgh; Karin Vanderkerken; Helena Jernberg Wiklund
Journal:  Oncotarget       Date:  2015-08-21

8.  Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their niche.

Authors:  Jérémie Gaudichon; Francesco Milano; Julie Cahu; Lætitia DaCosta; Anton C Martens; Jack-Michel Renoir; Brigitte Sola
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

9.  Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.

Authors:  Gijs van Haaften; Gillian L Dalgliesh; Helen Davies; Lina Chen; Graham Bignell; Chris Greenman; Sarah Edkins; Claire Hardy; Sarah O'Meara; Jon Teague; Adam Butler; Jonathan Hinton; Calli Latimer; Jenny Andrews; Syd Barthorpe; Dave Beare; Gemma Buck; Peter J Campbell; Jennifer Cole; Simon Forbes; Mingming Jia; David Jones; Chai Yin Kok; Catherine Leroy; Meng-Lay Lin; David J McBride; Mark Maddison; Simon Maquire; Kirsten McLay; Andrew Menzies; Tatiana Mironenko; Lee Mulderrig; Laura Mudie; Erin Pleasance; Rebecca Shepherd; Raffaella Smith; Lucy Stebbings; Philip Stephens; Gurpreet Tang; Patrick S Tarpey; Rachel Turner; Kelly Turrell; Jennifer Varian; Sofie West; Sara Widaa; Paul Wray; V Peter Collins; Koichi Ichimura; Simon Law; John Wong; Siu Tsan Yuen; Suet Yi Leung; Giovanni Tonon; Ronald A DePinho; Yu-Tzu Tai; Kenneth C Anderson; Richard J Kahnoski; Aaron Massie; Sok Kean Khoo; Bin Tean Teh; Michael R Stratton; P Andrew Futreal
Journal:  Nat Genet       Date:  2009-03-29       Impact factor: 38.330

10.  Ras oncogene mutation in multiple myeloma.

Authors:  A Neri; J P Murphy; L Cro; D Ferrero; C Tarella; L Baldini; R Dalla-Favera
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.